Logo

Illumina, Glaxo Pen SNP-Marker Collaboration

Sep 19, 2002

NEW YORK, Sept. 19 - Illumina and GlaxoSmithKline will turn a "large" set of SNP markers into SNP assays that Illumina will use to create a whole-genome linkage disequilibrium-mapping product to be deployed with its BeadArray platform, the companies said today.

 

Meantime, Glaxo will use the platform to genotype patient samples and disease populations, and will evaluate the use of high-density SNP-evaluation studies in the search for disease loci, according to Illumina.

 

The partners will co-create "performance criteria," evaluate candidate SNP markers, and select an "extensive" set for assay development. Illumina said the assay development will take place "over several month."

 

Click here for more information.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.